Antibiotics (Nov 2022)

The Effect of Dalbavancin in Moderate to Severe Hidradenitis Suppurativa

  • Elisa Molinelli,
  • Claudia Sapigni,
  • Giovanni Marco D’Agostino,
  • Valerio Brisigotti,
  • Giulio Rizzetto,
  • Ivan Bobyr,
  • Oscar Cirioni,
  • Andrea Giacometti,
  • Lucia Brescini,
  • Sara Mazzanti,
  • Annamaria Offidani,
  • Oriana Simonetti

DOI
https://doi.org/10.3390/antibiotics11111573
Journal volume & issue
Vol. 11, no. 11
p. 1573

Abstract

Read online

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by painful nodules, abscesses, and fistulas, localized to the areas of the folds where apocrine glands are present: the armpits, groin, inframammary region, and genital or perineal region. The management is still challenging, and it includes mainly systemic antibiotics, immunosuppressors, and biologic agents. Antibiotics are frequently used in the management of HS for their anti-inflammatory, immunomodulatory, and antimicrobial properties, but no data have been reported regarding the use of dalbavancin in HS. The aim of our practice was to evaluate efficacy, flare, and disease-free survival after dalbavancin therapy in a selected population with HS. We report the experience of the Ancona Dermatology Clinic in treating HS flare-ups with dalbavancin and its rationale for use. Our observation shows that the use of dalbavancin is an effective and well-tolerated treatment for the management of Hurley stage II-III HS; currently, dalbavancin should be considered as a supportive therapy for selected patients.

Keywords